IRLAB is currently performing an in-depth analysis of all the generated data in the Ph 2b study of mesdopetam in PD-LIDs. While the outcome of this data will dictate the future of the asset, we believe that Gunnar Olsson's experience could be positive in future conversations with IPSEN. Olsson has been the Chairman of the Board of IRLAB since 2020 and has more than 30 years of experience in leading positions in the life science industry, including 25 years in AstraZeneca. He has been responsible for the development and launch of several global blockbuster drugs.
Aktuellt
SENASTE
